Meabco Inc is a privately held oncology biotechnology company based in Chicago, IL. Established in 2001, they are dedicated to developing breakthrough cancer therapy products that significantly improve the lives of those affected by cancer. Their focus lies in addressing three major therapeutic cancer challenges: pancreatic cancer, metastatic breast cancer, and palliative treatment of radiation and chemotherapy.
With a strong emphasis on patient-friendly administration and low toxicity, Meabco Inc aims to provide favorable outcomes in cancer treatment. Their unique products, such as BP-C1 and BP-C2, have shown promising results in both palliation and tumor control properties. Through ongoing clinical development and research, Meabco Inc is committed to making a positive impact in the field of oncology.
Generated from the website